CLINICAL_TRIALS ClinicalTrials.gov record update

Safety and Efficacy Study of Tislelizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Patients, a Prospective Open Single-site Trial（TACBIN-01）

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04922047
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:08.908805+00:00
Published At: 2021-06-11T00:00:00+00:00
Record Updated At: 2021-06-11
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Urinary Bladder Neoplasms", "Urologic Neoplasms", "Urogenital Neoplasms", "Antineoplastic Agents", "Urinary Bladder Diseases", "Tislelizumab Antineoplastic Agents, Immunological"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-06-11"
protocolSection.identificationModule.nctId: "NCT04922047"
protocolSection.identificationModule.officialTitle: "Safety and Efficacy Study of Tislelizumab Alone and in Combination With Bacille Calmette-Gu\u00e9rin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Patients, a Prospective Open Single-site Trial\uff08TACBIN-01\uff09"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.